Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’re hosting a virtual event tomorrow about the rise and unraveling of Moderna. My colleagues Jason Mast and Damian Garde will be there to talk about their coverage of the company, and you can ask them any questions! Register here .

The need-to-know this morning

Biohaven Pharmaceuticals said its drug for spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease, was rejected by the FDA . The protracted review of the drug, called troriluzole, was controversial because Biohaven relied on historical data to demonstrate proof of efficacy. The FDA, in its letter to Biohaven, cited biases and confounding factors in those hist

See Full Page